HQL H&Q Life Sciences Investors

Tekla Life Sciences Investors Announces Results of Annual Shareholders Meeting

BOSTON--(BUSINESS WIRE)--

The Board of Trustees of Tekla Life Sciences Investors (HQL), is pleased to announce the results from the Fund’s annual shareholder meeting held today.

Shareholders re-elected Oleg Pohotsky and William Reardon as Trustees of Tekla Life Sciences Investors.

The shareholders also ratified the selection of Deloitte & Touche LLP as the Independent Registered Public Accountants of the Fund for its fiscal year ending September 30, 2017.

In addition, the shareholders rejected a shareholder proposal to reorganize the Board of Trustees into one class with each Trustee subject to election each year.

Tekla Life Sciences Investors (NYSE: HQL) is a closed-end fund that invests in companies in the life sciences and other healthcare industry.

Tekla Capital Management LLC is a Boston, MA based healthcare-focused investment manager with approximately $3.1 billion of assets under management as of March 31, 2017. Tekla also serves as investment adviser to three other closed-end funds: Tekla Healthcare Investors (NYSE: HQH), Tekla Healthcare Opportunities Fund (NYSE: THQ) and Tekla World Healthcare Fund (NYSE: THW). Information regarding the Fund and Tekla Capital Management LLC can be found at www.teklacap.com.

Destra Capital Investments is the Fund’s marketing and investor support services agent. Please contact Destra Capital Investments at (877)855-3434 if you have any questions.

EN
15/06/2017

Underlying

HQLH&Q Life Sciences Investors

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on H&Q Life Sciences Investors

 PRESS RELEASE
Free
HQL H&Q Life Scienc...

Tekla Life Sciences Investors Paid Distribution

BOSTON--(BUSINESS WIRE)-- On March 29, 2018, Tekla Life Sciences Investors paid a distribution of $0.40 per share. It is currently estimated that this distribution is derived from net realized long-term capital gains and return of capital or other capital source. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sa...

March 29, 2018 1 EN
 PRESS RELEASE
Free
HQL H&Q Life Scienc...

Tekla Life Sciences Investors Announce Renewal of Share Repurchase Pro...

BOSTON--(BUSINESS WIRE)-- Tekla Life Sciences Investors (the “Fund”) announced today that its Board of Trustees authorized a renewal of its share repurchase program. The current share repurchase program allows the Fund to purchase in the open market up to 12% of its outstanding common shares for a one-year period ending July 14, 2018. The renewal will allow the Fund to purchase in the open market up to 12% of its outstanding common shares for a one year-period ending July 14, 2019. The Board authorized the share repurchase program as ...

March 22, 2018 1 EN
 PRESS RELEASE
Free
HQL H&Q Life Scienc...

Tekla Life Sciences Investors Declares Stock Distribution

BOSTON--(BUSINESS WIRE)-- On February 16, 2018, Tekla Life Sciences Investors declared a stock distribution of $0.40 per share. The record date for the stock distribution is February 28, 2018 and the payable date is March 29, 2018. The Fund will trade ex-distribution on February 27, 2018. This stock distribution will automatically be paid in newly issued shares of the Fund unless otherwise instructed by the shareholder. The shares will be valued at the lower of the net asset value or market price on the pricing date, March 23...

February 16, 2018 1 EN
Free Trial
HQL H&Q Life Scienc...

A director bought 1,300 shares at 21.037USD and

A director at Tekla Life Sciences Investors bought 1,300 shares at 21.037USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...

HQL H&Q LIFE SCIENCES INVESTORS
01/30/18 January 30, 2018 1 EN
 PRESS RELEASE
Free
HQL H&Q Life Scienc...

Tekla Life Sciences Investors Paid Distribution

BOSTON, Mass.--(BUSINESS WIRE)-- On December 29, 2017, Tekla Life Sciences Investors paid a distribution of $0.43 per share. It is currently estimated that this distribution is derived from net realized short-term gains and return of capital or other capital source. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized losses o...

December 29, 2017 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch